Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExp CTLA4/CD152, human recombinant protein
CTLA4, CD152, CELIAC3, GRD4, GSE, ICOS, IDDM12
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P16410 |
|---|---|
| Calculated MW | This protein is fused with 6×his tag at the C-terminus, and has a calculated MW of 14.3 kDa. The predicted N-terminus is Ala 37. DTT-reduced Protein migrates as 25 kDa in SDS-PAGE due to glycosylation. |
| Gene ID | 1493 |
|---|---|
| Gene Symbol | CTLA4 |
| Other Names | CTLA4, CD152, CELIAC3, GRD4, GSE, ICOS, IDDM12 |
| Gene Source | Human |
| Source | HEK293 cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its binding ability in a functional ELISA. Immobilized Human CTLA4 Protein at 2 µg/ml (100 µl/well) can bind rhB7-1/ CD80 Protein Fc Chimera with a linear range of 0.2 - 20 ng/ml, when detected by HRP labeled Goat anti Human IgG Fc PAb. Measured by its binding ability in a functional ELISA. Immobilized Human CTLA4 Protein at 1 µg/ml (100 µl/well) can bind rh PD-L1 /B7-H1 /CD274 Protein Fc Chimera with a linear range of 20 - 200 ng/ml, when detected by HRP labeled Goat anti Human IgG Fc PAb. |
| Target/Specificity | CTLA4/CD152 |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
References
Harper K.,et al.J. Immunol. 147:1037-1044(1991).
Ling V.,et al.Genomics 78:155-168(2001).
Gu M.,et al.Clin. Immunol. 128:374-381(2008).
Wu P.W.,et al.Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
Hillier L.W.,et al.Nature 434:724-731(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
